HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Prestige

This article was originally published in The Rose Sheet

Executive Summary

BCBG Max Azria fashion house signs licensing agreement with Unilever to develop a collection of fragrance and beauty products that will launch worldwide in the second half of 2000. The fragrance and cosmetics line will be sold in current BCBG retail outlets, including 114 free-standing stores, as well as Neiman Marcus, Bloomingdale's and Nordstrom. The BCBG license will be managed by the Unilever Prestige business unit of Unilever Cosmetics International, which was developed in March (1"The Rose Sheet" March 13, p. 3). The company has signed agreements with Nautica and Vera Wang

You may also be interested in...



Unilever Prestige Licensing Deals Sought Via New Marketing Unit

Unilever will boost its presence in the upscale fragrance and beauty market with the development of a new business unit, Unilever Prestige, the company announced March 7.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel